From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events

George A Diamond1, Sanjay Kaul

  • 1Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, Calif, USA. gadiamond@pol.net

Insights

This study unifies physical and biochemical models of ischemic heart disease into a kinetic model. It suggests cardiovascular events arise from transitions between inflammatory and stenotic states, impacting treatment strategies.

Area of Science:

  • Cardiovascular Pathophysiology
  • Biomedical Modeling

Background:

  • Ischemic heart disease management relies on two models: physical (vascular stenosis) and biochemical (plaque inflammation).
  • These models are often seen as competing, influencing interventional versus conservative treatment approaches.

Purpose of the Study:

  • To unify the physical and biochemical models of ischemic heart disease pathophysiology.
  • To develop a kinetic model characterizing cardiovascular events as transitions between inflammatory and stenotic states.
  • To provide a theoretical basis for predicting event causes and prevention strategies.

Main Methods:

  • Developed a kinetic model representing transitions between non-stenotic/non-inflammatory, inflammatory, and stenotic states.
  • Modeled the exponential changes in prevalence of these states over time.
  • Formulated event rate as a function of myocardial ischemia and vascular inflammation.

Main Results:

  • The model describes a decline in the normative state and a rise-then-fall pattern for inflammatory and stenotic states.
  • Cardiovascular event rates increase as a complex function of both ischemia and inflammation.
  • The model offers a framework to differentiate contributions of stenosis and inflammation to atherosclerotic events.

Conclusions:

  • The unified kinetic model reconciles competing perspectives in ischemic heart disease management.
  • It provides a theoretical foundation for personalized prevention strategies targeting plaque stabilization or ischemia relief.
  • Further prospective validation is needed to confirm the model's predictive capabilities.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...